Kornimate/medical-research-clean huggingface dataset:
validation of a real-time urodynamic measure of urinary urgency

Conditions: Overactive Bladder Syndrome

Summary: urinary urgency is a key symptom of overactive bladder syndrome (oab) and may be more bothersome to a patient than the symptom of urinary frequency. unfortunately, controversy continues to surround the term 'urgency' and there is no good tool to evaluate the severity of urgency. this fact has constrained the performance of clinical research in this field. the cause of urinary urgency is not fully understood and may vary from patient to patient. although clinicians regularly obtain measures of bladder sensation during cystometry, little attention has been paid to the patient experience of urinary urgency. in this study, the researchers will use a non-significant risk device (i.e., an urgeometer) to measure urinary urgency in women with overactive bladder.

at baseline, a small catheter is placed inside the participant's bladder. the bladder is filled with sterile water through the catheter. as the bladder is filled, the participant is asked to rate their urinary urgency using the urgeometer. the urgeometer lever marks a continuous scale from 0 'no urge at all' to 100 'maximum urge which you can tolerate'. the testing is stopped once the bladder is filled. to minimize the chance of infection, participants receive one dose of oral antibiotics prior to the bladder testing. following completion of the bladder test, participants will take 10mg solifenacin succinate (vesicarer) daily for 30 days. afterward, participants repeat the bladder test. the change in participants' maximal tolerated cystometric capacity (mcc) will be measured in milliliters and used to evaluate the effectiveness of the drug.

Eligibility criteria:
inclusion criteria: * have symptoms of urge or mixed incontinence (urge predominant) and desire treatment with anticholinergic medication. * demonstrated detrusor overactivity with or without incontinence during urodynamic testing. * are able to consent and fill out study documents, complete repeated urodynamic testing, and follow-up in 4 weeks. exclusion criteria: * have been treated with any anticholinergic medication in the previous month. * have an elevated post -void residual volume as determined during their routine clinical care. * have had a urinary tract infection in the last month, as determined by history. * have untreated narrow angle glaucoma, by patient history. * have a known allergy or intolerance to solifenacin, as determined by patient history.

Keywords: bladder urinary urgency solifenacin vesicare(r)
pivotal study of sebacia microparticles in the treatment of acne vulgaris

Conditions: Inflammatory Acne Vulgaris

Summary: prospective, randomized multicenter study to examine the safety and effectiveness of sebacia microparticles with or without laser in the treatment of moderate to moderately-severe inflammatory acne vulgaris


Eligibility criteria:
inclusion criteria: * males and females, 15 - 45 years of age * able to provide informed consent/assent; minors will provide assent while parent or legal guardian will provide consent * moderate to moderately severe (3 or 4) inflammatory acne vulgaris by investigator's global assessment * subject has 25 to 75 inflammatory lesions on the cheeks, chin and forehead, not concentrated in one area * subject has fitzpatrick skin phototype i, ii or iii * subject is in good health, willing to participate and able to comply with protocol requirements exclusion criteria: * severe acne (investigator's global assessment 5) with significant scarring potential and greater than 2 nodular lesions * clinically relevant history of keloids * facial tattoos * acne conglobata, acne fulminans, chloracne, drug-induced acne * active concomitant skin disease, excessive scarring or excess facial hair * heavily tanned skin; unable or unwilling to avoid tanning beds/excessive sun exposure * acne medication and therapy restrictions - time period prior to baseline (below) 1. oral retinoids - 6 months 2. other systemic medications - 4 weeks 3. topical retinoids, steroids, antibiotics - 2 weeks 4. otc topical treatments - 1 week 5. light treatments (including ipl or laser), microdermabrasion and/or peels - 8 weeks 6. investigational drug, biologic or device - 30 days 7. gold therapy of any type for any reason - excluded * pregnant, lactating, nursing or planning to become pregnant during the study period * known allergy to gold, ethanol, diisopropyl adipate, polysorbate 80 * clinically relevant condition that makes participation unsafe or that would interfere with study treatment and assessment
treatment of metastatic cancer in terminally diagnosed patients

Conditions: Metastatic Cancer

Summary: the objective is to provide terminally diagnosed patients with a last line of treatment while improving overall quality of life. tempol can be added to any chemotherapy regimen to potentially reduce side effects and overcome chemoresistance.

the objective is to provide terminally diagnosed patients assigned to palliative care and palliative chemotherapy a last line treatment with tempol. in vivo studies have shown tempol to work synergistically with a number of chemotherapy agents increasing treatment response and reducing chemoresistance. additionally, tempol has been shown to provide protection to non-cancerous cells allowing for increased chemotherapy dosing by reducing side effects. tempol inhibits hif-1/vegf among others in cancerous cells while upregulating gsh/nrf2 among others in non-cancerous cells.

Eligibility criteria:
inclusion criteria: * metastatic terminally diagnosed cancer exclusion criteria: -
prospective randomized trial comparing two techniques of sleeve gastrectomy

Conditions: Morbid Obesity

Summary: this study compares if there is any difference doing antrectomy while performing a sleeve gastrectomy for treating morbid obesity. the investigators compare the differences between leaving or not leaving the antrum in terms of food tolerance, weight lost and quality of life.


Eligibility criteria:
inclusion criteria: * bmi\>40 kg/m2 * age \>18 years old * eligible for laparoscopic surgery exclusion criteria: * prior bariatric surgery * sleeve gastrectomy as a part of a duodenal switch * second time surgery before 18 months * other procedures done during the surgery * conversion to laparotomy

Keywords: morbid obesity high risk
platelet-rich plasma for chronic lateral ankle instability

Conditions: Ankle Instability; Platelet-rich Plasma

Summary: this study aims to evaluate the effect of platelet-rich plasma (prp) on chronic lateral ankle instability by comparing the imaging and clinical outcomes between patients receiving prp and those receiving whole blood during the modified broström-gould procedure.

chronic lateral ankle instability (cai) in a common foot and ankle problem. it has been linked to recurrent ankle pain, swelling, and even early degenerative change if not properly treated. lateral ligament reconstruction using modified broström-gould procedure is the mainstream in treatment of cai. early mobilization is related to better functional outcome, and rapid healing of the repair is the key point to shorten the immobilization time. platelet-rich plasma (prp) is a fraction of plasma that contains platelets and multiple growth factors concentrated at high level. because activated platelets have the potential to release growth factors, prp has been clinically used to accelerate wound healing and tissue regeneration. however, there is no conclusion regarding the efficacy of prp on cai. this clinical trial will investigate the effect of prp on cai. eligible patients will be randomly assigned to receive prp or whole blood during the modified broström-gould procedure. the postoperative imaging and clinical outcomes will be compared and analyzed.

Eligibility criteria:
inclusion criteria: * age between 20 and 60 years * with diagnosis of chronic lateral ankle instability exclusion criteria: * poor controlled diabetes * peripheral artery obstructive disease * skin or soft tissue infection at ankle * with current or prior history of ankle disease, including degeneration arthritis, fracture, deformity, and cartilage disease. * with prior history of ankle surgery * with current or prior history of cancer * with current or prior history of hematological disease * pregnancy

Keywords: platelet-rich plasma ankle injuries lateral ligament, ankle
airway clearance study

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of the study is to evaluate how the airways in copd patients, compared to healthy volunteers, absorb steroid drugs from symbicort turbuhaler and seretide diskus. the blood concentrations of the steroids will be used as surrogate marker.


Eligibility criteria:
inclusion criteria: * copd patients: ≥40 years of age, diagnosed copd with symptoms ≥1 year, pre-bronchodilatory fev1 ≤55% of pn, productive cough with expectoration. * healthy volunteers: ≥18 years of age, healthy, pre-bronchodilatory fev1 \>80% of pn, non-smoker exclusion criteria: * copd patients: current respiratory tract disorder other than copd, asthma before 40 years of age, significant or unstable cardiovascular disorder, * healthy volunteers: use of any regular medication or therapy, pregnancy or breast-feeding,

Keywords: copd
urinary biomarkers for aki diagnosis in patients with sars-cov-2 (covid-19)

Conditions: COVID-19; Renal Replacement Therapy; Acute Kidney Injury

Summary: among patients with sars-cov-2 pneumonia, approximately 20% have an acute kidney injury (aki) and 5% require renal replacement therapy. occurrence of aki in patients with covid-19 is associated with increased morbidity and mortality. early detection of patients at risk of aki would allow to prevent onset or worsening of aki. the aim of this study is to determine if urine biomarkers of renal tubular damage such as timp-2 and igfbp7 could early identify patients with sars-cov-2 pneumonia at risk of developing aki.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * covid-19 confirmed by positive sars-cov-2 pcr * at least one urine sample exclusion criteria: * persons under protection * paritcipation rejections

Keywords: acute kidney injury sars-cov-2 renal replacement therapy
the value of bacterial loads by real time pcr in predicting recurrence of abnormal vaginal flora after oral metronidazole therapy

Conditions: Abnormal Vaginal Flora

Summary: abnormal vaginal flora is currently diagnosed among women (20-40%). it is associated with symptoms (bad smell, vaginal discharge) and adverse out-comes in pregnant and not pregnant women. the high recurrence rate raises the long-term effectiveness of therapy. the hypothesis is the persistence of bacteria associated with vaginal flora imbalance as atopobium vaginae and gardnerella vaginalis. at the present time there is a lack of an accurate marker for the risk of recurrence.

women with symptomatic abnormal vaginal flora (a nugent score of 4-10 or sup or egal 3 amsel criteria) will be enrolled. abnormal vaginal flora will be treated with 2g of oral metronidazole. follow-up will be performed at 1 week,1 month and 12 months after treatment. vaginal samples will be tested by quantitative real time pcr to determine the vaginal concentrations of a. vaginae, g. vaginalis, and lactobacillus spp.

Eligibility criteria:
inclusion criteria: * woman of more than 18 years, presenting vulvo-vaginal symptoms to type(chap) of smell or abnormal vaginal losses the day of the inclusion and having an imbalance of the vaginal flora objectivized by: * the presence of at least 3 clinical criteria of amsel ( 41 ) is a score of nugent \> 4 ( 42 ) * woman in genital encircled period of activity (negative pregnancy test in the inclusion) and under effective contraception, including an intra-uterine device (mechanical, hormonal). * woman ménopausée with or without hormonal treatment (by way oral, transcutaneous, sous cutaneous, vaginal). * woman encircled at the time of the inclusion. * having woman was treated(handled) for a vaginal infection or one imbalance of the vaginal flora more than 7 days ago. * woman having understood(included) the progress and the objectives of the study and having agreed to sign a lit(enlightened) consent. * only the profitable women of a national insurance scheme will be included exclusion criteria: * woman presenting a sexually transmitted infection (infection with gonococcus, with chlamydia trachomatis, with trichomonas vaginalis) revealing on the takings realized during the consultation of inclusion but the bacteriological results(profits) of which will be known only secondarily. * pregnant woman presenting to the consultation of inclusion of métrorragies either a break of the pocket of waters or an infectious complication of the pregnancy. * woman removing her consent during the study. * lost sight woman. * woman deprived of freedom, judicial or administrative; * woman hospitalized for quite other reason that looks for her(it); * woman hospitalized in a sanitary establishment or social in the other purposes that the research; * major woman except state to express its consent
effects of cultura yoghurt in irritable bowel syndrome (ibs) patients on intestinal and immunological changes

Conditions: Irritable Bowel Syndrome; Relief of Irritable Bowel Syndrome Symptoms; Quality of Life

Summary: to determine the effect of cultura probiotic yoghurt on number of responders to treatment during 8 weeks of treatment in comparison to placebo. to determine the effect of cultura yoghurt on change in total score of (ibs) irritable bowel syndrome severity index during 8 weeks of treatment in comparison to placebo in ibs out patients.

recent research has shown taht probiotic may give positive effect on symptoms among patients with (ibs) irritable bowel syndrome. the mechanism behind the positive effect are not known but a positive effect on different cytokines are a possible mechanism. also effect on the large intestine bacterial mass could be of importance.

Eligibility criteria:
inclusion criteria: signed consent to participate age 18-70 years ibs according to rome ii criteria - exclusion criteria: 1. participation in a clinical study one month prior to screening visit and throughout the study. 2. abnormal results of the screening laboratory tests clinically relevant for study participation, as judged by the investigator. 3. other gastrointestinal disease(s) that explains the patient's symptoms, as judged by the investigator. 4. other severe disease(s) such as malignancy, severe coronary disease, kidney disease or neurological disease, as judged by the investigator. 5. symptoms indicating other severe disease(s) such as gastrointestinal bleeding, loss of weight or fever, as judged by the investigator. 6. severe psychiatric disease as judged by the investigator. 7. previous history of drug or alcohol abuse six months prior to screening. 8. intolerance or allergy against milk products or gluten. 9. use of other probiotic products (according to sponsor's list) 2 weeks prior to the study and throughout the study. 10. consumption of antibiotic drugs 1 month prior to screening and throughout the study. 11. consumption of cortisone, nsaid or other anti-inflammatory drugs on a regular basis 2 weeks prior to screening and throughout the study. 12. pregnant or lactating or wish to become pregnant during the period of the study. 13. lack of suitability for participation in the study for any reason as judged by the investigator.

Keywords: ibs (irritable bowel syndrome) probiotic yoghurt symptom severity
assessment of facial symmetry following fibula free flap fixated in a prosthetically favorable position versus the inferior border position for mandibular reconstruction

Conditions: Mandible Reconstruction

Summary: the study aims to evaluate facial symmetry outcomes after mandibular reconstruction using fibula free flaps, comparing two fixation techniques: the prosthetically favorable position (alveolar level) and the conventional position (inferior border level).

the study aims to evaluate facial symmetry outcomes after mandibular reconstruction using fibula free flaps, comparing two fixation techniques: the prosthetically favorable position (alveolar level) and the conventional position (inferior border level). design: a randomized controlled trial with parallel groups and a 1:1 allocation ratio. the study will assess facial symmetry and patient satisfaction over 12 months post-surgery. population: patients requiring mandibular reconstruction due to conditions like tumors, trauma, or osteomyelitis, with mandibular defects greater than 9 cm. interventions: group 1: fibula free flap fixated at the alveolar level (prosthetically favorable position). group 2: fibula free flap fixated at the inferior border level (conventional position). setting: oral and maxillofacial surgery department, faculty of dentistry, cairo university. duration: follow-up over 12 months post-surgery, with key data collection points at baseline, 3 days, 1 week, 1 month, 6 months, and 12 months postoperatively.

Eligibility criteria:
inclusion criteria: * patient who requires mandibular resection due to tumor, trauma, osteomyelitis or osteoradionecrosis. * patient with mandibular defect \>9 cm. exclusion criteria: - patients with systemic condition counteracting with the surgical procedure.

Keywords: segmental mandibular defect mandibular reconstruction fibula free flap dental implants facial symmetry face scan.
ospm-enhanced ai model to identify premalignant and malignant ocular surface tumors

Conditions: Performance of the Model

Summary: an ospm-enhanced deep learning model has been developed for identifying premalignant and malignant tumors using data retrospectively collected from the ningbo eye hospital, jiangdong eye hospital, and the eye hospital of wenzhou medical university. to further substantiate the model's effectiveness, we intend to evaluate it prospectively at ningbo eye hospital.


Eligibility criteria:
inclusion criteria: ● ocular surface tumor images with histopathological findings exclusion criteria: ● low-quality images
effect of oral daily supplementation with 400 iu vs 200 iu of vitamin d in term healthy neonates

Conditions: Vitamin D Deficiency

Summary: the purpose of the study is to evaluate the effect of daily oral supplementation with vitamin d on serum vitamin d levels in term healthy newborns. it has been found in various studies that vitamin d is highly deficient in indian mother infant diads. there is a need to supplement vitamin d from neonatal period to prevent various metabolic disturbances due to vitamin d deficiency in later life. this study aims to find the effectiveness and the optimum dose of routine vitamin d supplementation in healthy term newborns for fulfilling the normal requirements in indian infants.

vitamin d deficiency is highly prevalent in india as reported in various studies. vitamin d supplementation is necessary as vitamin d is required not only for prevention of rickets as traditionally thought, but also for its emerging role in development of diseases such as myopathic disorders, proneness to infection, autoimmune disorders and cancers .however supplementation studies are limited and predominantly from foreign countries. moreover most of them report variable outcomes with no unanimous outcome with respect to optimum dose and duration of supplementation of vitamin d. various national authorities recommend different doses of vitamin d for supplementation. american academy of pediatrics, the institute of medicine of national academics, the drug and therapeutics committee of the lawson wilkins pediatric endocrine society, the canadian pediatric society and european society for pediatric endocrinology recommend that 400iu of vitamin d should be supplemented in all infants starting from within a few days of birth throughout childhood. espghan recommends 800-1000 iu for high risk infants, ireland recommends 200iu vitamin d per day, uk does not recommend any supplements upto 6 months of age , however if formula milk intake \<500ml/day then 300 iu is recommended. there are no such guidelines for india. hence this study aims at evaluating the proportion of vitamin d deficient

Eligibility criteria:
inclusion criteria: * gestation \> 37 weeks * birth weight \>2.5 kg * informed consent of one of the parents * place of residence\<10km exclusion criteria: * presence of gross congenital malformation * need of resuscitation at birth * need for admission to neonatal icu * refusal of consent

Keywords: oral daily supplementation with vitamin d for 6 months
the brain metabolic change in chronic cancer pain patient: fdg pet image study

Conditions: Cancer Pain

Summary: cancer pain deteriorated in quality of life and related with numerous psychosocial problems. over the one third of cancer patient suffered from moderate to severe cancer pain, even under adequate pain management. the 18f-fluoro-2-deoxyglucose (fdg) positron emission tomography/computed tomography (pet/ct) images can provide quantitative results in clinical oncology. as a functional neuroimaging, the pet evidently provided anatomical activated regions, size, and spatial extent information. in this study, we use fdg-pet to investigate changes concerning the glucose metabolism in the brain with or without cancer pain. therefore, we may provide useful information to treatment target in cancer pain patients.

overall, cancer incidence has decreased and the rate of cancer deaths in both men and women has also significantly declined among both men and women in all site.however, the prevalence of chronic pain is 28.2%, ranging from 22.5% to 35.4%, depending on the location of the primary tumor, and neuropathic characteristics were observed in 19.9% of patients with chronic cancer pain. despite numerous studies on cancer pathogenesis and diagnosis, few reports have demonstrated the brain mechanism underlying cancer pain. one study used resting functional magnetic resonance imaging (fmri) to identify the changes in the functional brain network of chronic bone cancer pain mice under anesthesia. cancer-induced bone pain (cibp) might alter resting state activity of the cingulate cortex, prefrontal cortex (pfc) and ventral striatum, indicating a strong affective component of the cibp mice.in imaging studies of human patients with cancer, patients with chronic cancer pain exhibited activation in the pfc. the 18f-fluoro-2-deoxyglucose (fdg) positron emission tomography/computed tomography (pet/ct) images can provide quantitative results in clinical oncology.owing to the higher glucose metabolic rate in the brain, brain fdg-pet images are not routinely used in the clinical setting. however, several studies have demonstrated functional brain changes in human pain condition.in this study, we use fdg-pet to investigate changes concerning the glucose metabolism in the brain with or without cancer pain.

Eligibility criteria:
inclusion criteria: 1. cancer patients who scheduled whole body fdg-pet image scan for clinically indicated. 2. age \> 20 exclusion criteria: 1. unable to complete questionnaires. 2. prior evidence of brain metastases.